PubMed Health⌕ Search

Biomedical subjects

P Lenehan

Publications and source records attributed to P Lenehan.

13 recordsLinked to original sources
PubMed2006

Cervical screening history in patients with early stage carcinoma of the cervix.

This study aimed to examine whether a decade of heightened publicity on issues relating to cervical screening has changed the screening profile of women presenting with cervical cancer at the National Maternity Hospital. The screening history of 100 women diagnosed with early/surgically treated cervical cancer between 1998 and 2002 was compared with a similar study conducted in 1982 /1990. The percentage of women never screened was similar - 24 %( 2002) and 23% (1990). The interval between last recorded smear and diagnosis of disease was greater than 5 years in 45.6% and 41.7% respectively. Overall 60% of women in the recent period had either failed to avail of screening or were not screened within 5 years of diagnosis compared with 64% in 1990. Multiparous women comprised 90% of the study group and 50% of those inadequately screened were attending their general practitioner on a regular basis - therefore affording a potential for opportunistic screening The current method of screening has failed in this group and has not improved in 10 years despite of increased population awareness and greater opportunities for screening than ever before and would support an argument for a National Screening Program.

Adenocarcinoma↗
PubMed2004

Bowel evisceration.

Explore the source record for details and available documents.

Endometrial Neoplasms↗
PubMed2001

Phase 1 drug interaction study of suramin and warfarin in patients with prostate cancer.

Potential interaction between suramin and warfarin was evaluated when coadministered to patients with cancer. Thirteen men with advanced hormone-refractory prostate cancer were initially stabilized with warfarin to a prothrombin time (PT) of 2 +/- 0.2 International Normalized Ratio (INR) during a lead-in period of 4 weeks. A baseline daily warfarin dose was established, and treatment with suramin plus hydrocortisone was then started. The effect of suramin on the anticoagulant activity of warfarin was assessed in each patient by comparing his baseline warfarin dose with average daily doses required to maintain the same INR level over each of the initial 6 weeks of a 12-week course of suramin treatment. The average daily dose of warfarin required to maintain PT at 2 +/- 0.2 INR decreased from a baseline value of 4.2 to between 3.4 and 4.0 during the 6 weeks of suramin plus warfarin treatment. Despite failing to demonstrate equivalence applying a 90% confidence interval approach, required reductions in warfarin dose were clinically minor and the combination was well tolerated. Based on these results, the eligibility criteria for a large ongoing randomized study were amended to allow entry of men receiving warfarin therapy. This interaction study, together with experience gained in a larger trial setting, has confirmed that warfarin and suramin can be safely coadministered, provided that coagulation status is appropriately monitored.

Anti-Inflammatory Agents↗
PubMed1990

Distant metastases following surgical treatment of cervical carcinoma.

Fifty patients with early carcinoma of the cervix were treated by radical hysterectomy and pelvic lymphadenectomy. Twelve patients (24%) had positive nodes and received adjuvant pelvic radiotherapy. The mean duration of follow-up was seven years and all patients had at least four years follow-up. Five patients died from recurrence; four from isolated distant metastases and one from a pelvic side wall recurrence. The disease-free interval for patients with distant metastases was six months to two years and the metastases were to lung and bone.

Adult↗
PubMed1987

Pregnancy and vaginal delivery following bilateral total hip replacement.

We report a case of pregnancy with spontaneous vaginal delivery in a patient who had bilateral total hip arthroplasty. Guidelines for management of such patients are discussed, as this is a clinical situation which is likely to be seen more frequently. Orthopaedic consultation is important, if possible with the surgeon who performed the operations.

Adult↗
PubMed1985

The treatment of grade 3 cervical intraepithelial neoplasia with cryotherapy: an 11-year experience.

The results of treatment of 453 patients with grade 3 cervical intraepithelial neoplasia by cryotherapy are presented. After excluding 31 patients who were lost to follow-up, the failure rate of primary treatment in the remaining 422 patients was 7.1% (30 patients). Outpatient re-treatment of those with persistent disease achieved an overall cure rate of 98%. Statistical analysis to determine prognostic significance with regard to persistent disease was carried out on the following variables: grade, size, and type of freeze. Type of freeze was the only variable to show statistical significance. Cryotherapy remains an effective outpatient modality for the treatment of grade 3 cervical neoplasia. A rigid protocol of patient selection and meticulous cryotherapy technique play a large role in obtaining the high cure rates reported in this study.

Adolescent↗
PubMedDate not supplied

Endometrial pipelle biopsy compared to conventional dilatation and curettage.

Dilatation and curettage (D + C) is the most common operation performed in Britain. The liberal use of D + C has been criticised. The objective of this study was to evaluate the use of outpatient endometrial pipelle biopsy and determine its safety in terms of detecting abnormalities. Complications and financial costs were also evaluated. Data were reviewed from an active gynaecological unit from February 1993 to January 1995. A total of 303 D + Cs and 104 endometrial pipelle biopsies were performed in this period. Nine malignancies were detected by D + C and 1 by pipelle biopsy. A total of 24 and 3 benign abnormalities were detected by each method respectively. There was a higher complication rate in the D + C group but the failure rate was higher in the endometrial pipelle biopsy group. The monetary savings over this period is estimated at 20,307 pounds. There were no missed malignancies to our knowledge over the 8 yr period since endometrial pipelle biopsy was introduced to the hospital.

Adult↗
PubMedDate not supplied

Recurrent ovarian carcinoma: diagnosis and second-line therapy.

Approximately 10% of patients with ovarian cancer will develop a recurrence. Successful treatment of recurring disease has been documented, and recent developments in chemotherapy are encouraging. In our study, CA125 Tumour Marker was a useful marker to monitor the course of such disease, and detected recurring ovarian cancer at a sub-clinical level, leading to earlier diagnosis. This may have implications for outcome.

Adult↗